Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Liabilities and Shareholders Equity (2022 - 2025)

Envoy Medical's Liabilities and Shareholders Equity history spans 4 years, with the latest figure at $8.6 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $8.6 million for Q4 2025, down 25.83% from a year ago — trailing twelve months through Dec 2025 was $37.0 million (up 2.41% YoY), and the annual figure for FY2025 was $8.6 million, down 25.83%.
  • Liabilities and Shareholders Equity for Q4 2025 was $8.6 million at Envoy Medical, up from $8.2 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $427.8 million in Q3 2022 to a low of $2.6 million in Q4 2022.
  • The 4-year median for Liabilities and Shareholders Equity is $10.1 million (2025), against an average of $92.3 million.
  • Peak annual rise in Liabilities and Shareholders Equity hit 223.59% in 2023, while the deepest fall reached 95.04% in 2023.
  • Year by year, Liabilities and Shareholders Equity stood at $2.6 million in 2022, then skyrocketed by 223.59% to $8.3 million in 2023, then soared by 39.5% to $11.5 million in 2024, then dropped by 25.83% to $8.6 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $8.6 million, $8.2 million, and $9.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.